Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 3.5% – Here’s What Happened

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) shares were down 3.5% on Wednesday . The company traded as low as $2.95 and last traded at $3.06. Approximately 2,110 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 6,308 shares. The stock had previously closed at $3.17.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on EPRX shares. RODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective on the stock.

Eupraxia Pharmaceuticals Stock Performance

The stock has a market cap of $83.48 million and a PE ratio of -4.25. The stock has a fifty day simple moving average of $3.19 and a two-hundred day simple moving average of $2.83.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. On average, equities analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.67 EPS for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.